A detailed history of Prosight Management, LP transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 314,800 shares of MIRM stock, worth $12.2 Million. This represents 3.36% of its overall portfolio holdings.

Number of Shares
314,800
Previous 465,000 32.3%
Holding current value
$12.2 Million
Previous $11.7 Million 7.85%
% of portfolio
3.36%
Previous 3.36%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$23.57 - $34.85 $3.54 Million - $5.23 Million
-150,200 Reduced 32.3%
314,800 $10.8 Million
Q1 2024

May 15, 2024

BUY
$24.92 - $30.02 $4.28 Million - $5.15 Million
171,699 Added 58.54%
465,000 $11.7 Million
Q4 2023

Feb 14, 2024

SELL
$27.14 - $34.93 $1.63 Million - $2.1 Million
-60,207 Reduced 17.03%
293,301 $8.66 Million
Q3 2023

Nov 14, 2023

SELL
$24.63 - $32.85 $7.92 Million - $10.6 Million
-321,492 Reduced 47.63%
353,508 $11.2 Million
Q2 2023

Aug 14, 2023

BUY
$23.51 - $30.09 $2.52 Million - $3.22 Million
107,174 Added 18.87%
675,000 $17.5 Million
Q1 2023

May 12, 2023

BUY
$19.19 - $24.1 $4.97 Million - $6.24 Million
259,050 Added 83.9%
567,826 $13.6 Million
Q4 2022

Feb 14, 2023

BUY
$17.59 - $23.83 $418,219 - $566,582
23,776 Added 8.34%
308,776 $6.02 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $2.47 Million - $3.64 Million
123,473 Added 76.44%
285,000 $5.99 Million
Q2 2022

Aug 12, 2022

BUY
$18.42 - $27.5 $1.61 Million - $2.41 Million
87,597 Added 118.49%
161,527 $3.14 Million
Q1 2022

May 16, 2022

BUY
$15.5 - $23.93 $1.15 Million - $1.77 Million
73,930 New
73,930 $1.63 Million
Q1 2021

May 14, 2021

SELL
$16.29 - $21.92 $981,472 - $1.32 Million
-60,250 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$15.75 - $25.45 $948,937 - $1.53 Million
60,250 New
60,250 $1.05 Million

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.43B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Prosight Management, LP Portfolio

Follow Prosight Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.